Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks FadeBenzinga · 2 days ago
Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetGlobeNewsWire · Oct 8, 2026
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in TherapyGlobeNewsWire · Oct 5, 2026
Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 14,493 Shares of StockDefense World · Sep 22, 2026
Pharvaris (NASDAQ:PHVS) Insider Anne Lesage Sells 20,000 SharesDefense World · Sep 22, 2026
Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) StockDefense World · Sep 16, 2026Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.75 | -$0.81 | Miss |
| May 12, 2026 | -$0.82 | -$0.70 | Beat |
| Apr 2, 2026 | -$0.71 | -$0.85 | Miss |
| Nov 12, 2025 | -$0.78 | -$0.70 | Beat |
| Aug 12, 2025 | -$0.87 | -$0.94 | Miss |
| May 13, 2025 | -$0.80 | -$0.89 | Miss |